As biosimilar competition nears for Roche and its subsidiary, Genentech, a new WARN notice in the state of California disclosed that Genentech is set to lay off 223 employees from a local plant beginning August 31, 2018.
As biosimilar competition nears for Roche and its subsidiary, Genentech, a new WARN notice posted in the state of California disclosed that Genentech is set to lay off 223 employees from a local plant beginning August 31, 2018.
“The success of our business depends on our ability to respond to change, appropriately allocate resources and manage our operations efficiently,” said a Genentech spokeswoman in a statement. The layoffs will be “across different departments” and will continue into November.
These cuts come less than a year after the company laid off 130 workers at its biologics plant in Vacaville, California. “We are making this organizational change in response to the current and anticipated production requirements, the volumes required for some of our new medicine formulations, and shift schedule adjustments,” said the company at the time.
Roche’s top selling cancer medications rituximab (Rituxan), trastuzumab (Herceptin), and bevacizumab (Avastin) together brought in the company more than $20 billion in 2017. The high earnings have identified the drugs as valuable targets for biosimilar developers.
Although the FDA has approved a trastuzumab biosimilar (Ogivri) and bevacizumab biosimilar (Mvasi), neither have yet reached the market. The United States came close this year to having an approved rituximab biosimilar, however, the drug developer (Sandoz) was issued a Complete Response Letter from the FDA in May.
Conversely, the European market has seen approvals and marketing efforts of biosimilars for all 3 reference products; including 1 biosimilar option for Avastin, 4 Herceptin biosimilars, and 6 Rituxan biosimilars (1 molecule marketed under 4 trade names, and another molecule marketed under 2 trade names).
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.